CTXR Stock Analysis: Buy, Sell, or Hold?
CTXR - Citius Pharmaceuticals Inc. Common
$0.58
-0.02 (-3.81%)
▼
5d:
-15.9%
30d:
-18.29%
90d:
-28.92%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 14, 2026
Get Alerted When CTXR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called CTXR this week
0% bullish • 1 bearish
0% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CTXR is down 15.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CTXR is down 15.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CTXR is currently trading at $0.58, which is considered fair relative to its 30-day fair value range of $0.60 to $0.78. From a valuation perspective, the stock is trading at a discount (Forward PE: -0.7) compared to its historical average (0.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CTXR is in a downtrend. Immediate support is located at $0.51, while resistance sits at $0.73. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+589.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTXR is in a downtrend. Immediate support is located at $0.51, while resistance sits at $0.73. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+589.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.60 -
$0.78
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 589.3% below Wall St target ($4.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to -15.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.60 -
$0.78
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.51
Resistance Level
$0.73
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.72
Wall Street Target
$4.00
(+589.3%)
PE vs Historical
-0.7 vs 0.3
CHEAP
Share & Embed Analysis
Last updated: June 03, 2026 11:12 PM ET
Data refreshes hourly during market hours. Next update: 12:12 AM
Data refreshes hourly during market hours. Next update: 12:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTXR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 52 HOLD |
